In 1972, the World Health Organization (WHO) Male Task Force concluded that a long-acting gestagen to suppress pituitary gonadotropin secretion, and hence testicular activity, supplemented by androgen replacement therapy, was the way to develop a male contraceptive. But which gestagen, and which androgen, in what dose, and by what route of administration? These questions still remain, 32 years later, although the latest Australian study,1 has shown that three-monthly injections of 300 mg depot medroxyprogesterone acetate and four-monthly implants of 800 mg testosterone give excellent contraceptive protection for one year.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.